Innocan Pharma (IPO) πŸŽ‰
Innocan Pharma (IPO) πŸŽ‰

Innocan Pharma (IPO) πŸŽ‰

Categories
CannabisPharma
Description
InnoCan aims to harness the power of cannabinoids to target a wide variety of health problems. InnoCan plans to initially innovate new dermatology treatments, where research shows topical cannabinoid-combined treatments are highly effective. Innocan went public on the Canadian Stock Exchange in 2020.
Investment Year
2018
Founders
Yoram Drucker Iris Bincovitch
Founding Year
2018
HQ Location
Tel Aviv, Israel
Other Investors
IPO πŸŽ‰
Lead Partner
Yehuda Leibler

Press